The deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC development.
An article from
The deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis’ entry into ADC development.
Published July 6, 2026
Permission granted by Novartis
Novartis, aiming to bolster its oncology portfolio, will acquire the privately held Myricx Bio and gain its pipeline of “differentiated” antibody drug conjugates for up to $1.5 billion.
Novartis commits $1.1B upfront to take Myricx Bio and its next-gen ADC platform
Novartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Push - Novartis (NYSE:NVS)
London's Myricx Bio lands up to $1.5B Novartis exit after raising just $121M — TFN
Novartis acquires British start-up Myricx Bio
Novartis buys UK biotech Myricx for up to $1.5bn to chase a new cancer-drug class
Novartis rileva Myricx Bio in un’operazione fino a 1,5 miliardi di dollari
Correction to Novartis Article
Patent cliff fuels Novartis' $1.5bn swoop for London biotech
Novartis: rileva gruppo biotecnologie Myricx Bio per 1,1 mld $
Aussie super funds hit the jackpot in $2b UK biotech deal
Novartis pays $1.1B upfront (up to $1.5B total) for Myricx Bio, gaining its NMT inhibitor ADC payload platform and two…
Novartis acquires Myricx Bio for up to $1.5B to boost its oncology pipeline with a novel next-gen ADC cancer platform. Read more.
Novartis has agreed to acquire London biotech Myricx Bio for up to $1.5 billion, believing on its NMT inhibitor payload as a…
The Swiss pharma giant will pay $1.1 billion (CHF883 million) to acquire Myricx Bio, which is developing antibody-drug conjugates…
Novartis will pay $1.1bn upfront and up to $400m in milestones for Myricx Bio, a UK firm developing a novel payload for…
Da inizio anno sono state concluse 23 operazioni di M&A nel biotech per un controvalore di 94 miliardi di dollari, contro 103…
